Table 4.
Outcome of the largest cohort of patients with FA who underwent transplantation from matched unrelated donors
| Reference | Patients (n) | Conditioning regimens | Follow-up | aGVHD | cGVHD | TRM/NRM | OS | Secondary malignancies |
|---|---|---|---|---|---|---|---|---|
| Wagner et al49 (2007) | 98 | No Flu (Cy ± Bus ± ATG + IRR) Yes Flu (Flu + Cy ± ATG ± IRR ± Bus) |
3 years | 16% Flu + TCD 70% No Flu No TCD |
31% | 47% Flu 81% no Flu at 3 years |
52% Flu 13% no Flu at 3 years |
NR |
| Peffault de Latour et al26 (2013) | 176 post-1999 | Flu ATG ± IRR | 6 years | 36% (grades III-IV) | 16% at 5 years | 27% at 5 years | 64% at 5 years | 15 years CI 15% overall |
| Bernard et al48 (2021) | 23 | Flu-Cy-alemtuzumab or ATG | 74.4 months | 6.1% overall | 2.4% overall |
13.8% overall | 95.7% at 5 years | NR |
| Bonfim et al34 (2022) | 51 | Flu-Cy-ATG | 5 years | 16% | 27% | NR | 83% | NR |
| Modified from Pierri et al.13 | ||||||||
| ATG, antithymocyte globulin; Bus, busulfan; Cy, cyclophosphamide; Flu, fludarabine; IRR, irradiation in conditioning regimen; NR, not reported; TAI, thoraco-abdominal irradiation; TBI, total body irradiation; TLI, total lymph node irradiation; TRM/NRM, transplant-related mortality/nonrelapse mortality. | ||||||||